1065073-37-1 Usage
General Description
4-Bromomethyloxazole, also known as 5-Bromo-2-hydroxyimidazole, is a chemical compound with the molecular formula C4H3BrN2O2. It is an oxazole derivative and is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-Bromomethyloxazole possesses both a bromo and hydroxy group attached to the oxazole ring, making it a useful building block for the preparation of various organic compounds. It is commonly used in laboratory research and drug development processes due to its versatile reactivity and ability to undergo various chemical transformations. Additionally, 4-Bromomethyloxazole has been identified as a potential inhibitor of certain enzymes and has shown promise in the treatment of various diseases and medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1065073-37-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,5,0,7 and 3 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1065073-37:
(9*1)+(8*0)+(7*6)+(6*5)+(5*0)+(4*7)+(3*3)+(2*3)+(1*7)=131
131 % 10 = 1
So 1065073-37-1 is a valid CAS Registry Number.
1065073-37-1Relevant articles and documents
SUBSTITUTED OXOPYRIDINE DERIVATIVES
-
Paragraph 0603-0604, (2017/11/07)
The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
SUBSTITUTED OXOPYRIDINE DERIVATIVES
-
Paragraph 0841; ,0842; 0843, (2016/10/11)
The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
